NKB Neuron Activation for Drug Reward Suppression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The conventional understanding of dopamine 1 and dopamine 2 receptor medium spiny neurons in the nucleus accumbens does not fully account for distinct roles in drug addiction, particularly in regulating reward behavior, leaving a gap in treating drug addiction effectively.
Innovation Solution
Activating neurokinin B-expressing dopamine 1 receptor neurons, specifically in the nucleus accumbens, through methods such as optogenetics, chemogenetics, or deep brain stimulation, to modulate neuronal activity and reduce drug reward behavior.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Loss of information
If conventional dopamine 1 and dopamine 2 receptor medium spiny neuron models are used to understand addiction, then general reward regulation is explained, but distinct roles in drug addiction and reward behavior remain unclear
Solution Approach 1:
The patent segments the homogeneous D1-MSN population into distinct subtypes based on neurokinin B expression patterns. By identifying NKB-expressing D1-MSNs as a separate functional subclass, the invention reveals distinct roles in reward behavior and addiction that were previously obscured in conventional D1/D2 dichotomous models.
Solution Approach 2:
The patent applies local quality by identifying specific molecular markers (neurokinin B) within the broader D1-MSN population to define functionally distinct subtypes. This allows different regions or subpopulations of D1-MSNs to have specialized roles in addiction and reward processing, rather than treating all D1-MSNs as uniform.
2Reliability
If NKB-expressing neurons are activated to reduce drug reward behavior, then addiction treatment efficacy is improved, but treatment methodology complexity increases
Solution Approach 1:
The patent replaces complex mechanical neural stimulation systems with pharmacological agents that naturally activate NKB-expressing neurons. By using endogenous neuropeptides or their receptor agonists, the treatment achieves specific neuronal activation without requiring invasive optogenetic or chemogenetic delivery systems.
Solution Approach 2:
The patent introduces NKB-expressing neurons as an intermediary target between drug administration and reward behavior modulation. By identifying and activating this specific neuronal population as a mediator, the treatment achieves reliable addiction efficacy through a defined biological pathway rather than direct behavioral intervention.
3Manufacturing precision
If specific NKB-expressing dopamine 1 receptor neurons are targeted in the nucleus accumbens, then precision of addiction treatment is improved, but difficulty of detecting and measuring these neurons increases
Solution Approach 1:
The patent uses molecular markers and imaging techniques that detect specific properties (analogous to color changes) of NKB-expressing neurons. By identifying unique molecular signatures such as neurokinin B expression patterns and associated receptors, the invention enables precise detection and measurement of these specific neuronal subtypes in the nucleus accumbens.
Solution Approach 2:
The patent creates molecular copies or proxies for detecting NKB-expressing neurons, such as using receptor agonists that bind specifically to markers on these neurons. This allows indirect detection and measurement of the target neuronal population through their molecular signatures rather than direct observation.
Data Source
AI summary
Provided herein are methods for treating drug addiction in a subject, the method comprising activating neurokinin B (NKB)-expressing neurons of the subject. Also provided herein are compositions useful for the treatment of drug addiction in a subject by activating neurokinin B (NKB)-expressing neurons.